scholarly journals The effects of golimumab on radiographic progression in rheumatoid arthritis: Results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy

2011 ◽  
Vol 63 (5) ◽  
pp. 1200-1210 ◽  
Author(s):  
Paul Emery ◽  
Roy Fleischmann ◽  
Désirée van der Heijde ◽  
Edward C. Keystone ◽  
Mark C. Genovese ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Radiographic Progression ◽  
Methotrexate Therapy ◽  
Randomized Controlled ◽  
Randomized Controlled Studies

Erratum: The effects of golimumab on radiographic progression in rheumatoid arthritis: Results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy

2012 ◽  
Vol 64 (4) ◽  
pp. 1045-1045
Author(s):  
Paul Emery ◽  
Roy Fleischmann ◽  
Désirée van der Heijde ◽  
Edward C. Keystone ◽  
Mark C. Genovese ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Radiographic Progression ◽  
Methotrexate Therapy ◽  
Randomized Controlled ◽  
Randomized Controlled Studies

scholarly journals Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate

2018 ◽  
Vol 77 (11) ◽  
pp. 1566-1572 ◽  
Author(s):  
Josef S Smolen ◽  
Ronald F van Vollenhoven ◽  
Stefan Florentinus ◽  
Su Chen ◽  
Jessica L Suboticki ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Radiographic Progression ◽  
Methotrexate Therapy ◽  
Joint Disease ◽  
Link Type ◽  
Early Ra ◽  
Disease Characteristics ◽  
Structural Progression ◽  
Insufficient Response

ObjectivesMethotrexate is considered to be first-line therapy for rheumatoid arthritis (RA). However, a substantial proportion of treated patients do not achieve the desired goals of therapy. This analysis aimed to identify predictors of insufficient response to methotrexate in patients with early RA.MethodsThe Optimal Protocol for Treatment Initiation with Methotrexate and Adalimumab (OPTIMA) and PREMIER studies in patients with RA for <1 and <3 years, respectively, examined the efficacy of methotrexate and adalimumab in methotrexate-naive patients. This post hoc analysis included patients for whom initial methotrexate monotherapy was not successful after 6 months. Candidate predictors of insufficient response and clinically relevant radiographic progression (CRRP) included demographics, baseline disease characteristics and time-averaged disease variables over a 12-week interval. In OPTIMA, adalimumab was added to therapy after insufficient treatment response; in PREMIER, initial methotrexate therapy was continued; clinical, functional and radiologic outcomes were assessed after 1 year.ResultsBaseline 28-joint Disease Activity Score based on C-reactive protein (DAS28(CRP)) and time-averaged DAS28(CRP) over 4, 8 and 12 weeks were the strongest predictors of insufficient response to methotrexate and CRRP. Addition of adalimumab to methotrexate therapy was associated with better clinical, functional and radiographic outcomes after 1 year compared with continuing on methotrexate monotherapy.ConclusionsIn patients with early RA, baseline disease characteristics and early disease activity can predict response to methotrexate treatment and radiographic progression at 6 months. The addition of adalimumab at 6 months after methotrexate failure is associated with improved outcomes. These results support treatment-to-target strategies and timely adaptation of therapy in patients with early RA.Trial registration numberNCT00420927, NCT00195663; Post-results.

scholarly journals Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial

2004 ◽  
Vol 50 (11) ◽  
pp. 3432-3443 ◽  
Author(s):  
E. William St. Clair ◽  
D�sir�e M. F. M. van der Heijde ◽  
Josef S. Smolen ◽  
Ravinder N. Maini ◽  
Joan M. Bathon ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Randomized Controlled Trial ◽  
Early Rheumatoid Arthritis ◽  
Controlled Trial ◽  
Methotrexate Therapy ◽  
Randomized Controlled
Sign in / Sign up

Export Citation Format

Share Document